S6 Ep2: Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

from Treating Together · host Targeted Oncology

In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan for the treatment of patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received prior systemic therapy.

Episode metadata supplied by the publisher feed · Published Feb 6, 2025

Embed this episode

Attribution link and audio player

Ready to play

S6 Ep2: Behind the FDA Approval of Dato-DXd in HR+/HER2– Breast Cancer With Bardia

0:00 8:13

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Treating Together?

This episode is 8 minutes long.

When was this Treating Together episode published?

This episode was published on February 6, 2025.

Can I download this Treating Together episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!